Search
Dbv Technologies SA
DBVTAdd to Watchlist
15.820USD
+0.090+0.57%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
745.43MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.57%
5 Days
-1.25%
1 Month
-13.22%
6 Months
-16.96%
Year to Date
-17.48%
1 Year
+53.59%
Key Figures
15.830Open
16.410High
195.92KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.42%Turnover Ratio
15.730Prev. Close
15.570Low
2.32MTurnover
LossP/E Static
4.42P/B
0.00%Div Yield TTM
-105.67%ROA
26.18552wk High
0.94Volume Ratio
-113.92MNet Profit
47.12MShares
-4.5004EPS TTM
-0.99Beta
-158.91%ROE
7.52652wk Low
5.34%Amplitude
100.00%Gross Margin
745.43MMarket Cap
-2.83Reward/Risk
3.93%Risk Rate
TradingKey Stock Score of Dbv Technologies SA
Currency: USD Updated: 2026-07-02Key Insights
Dbv Technologies SA's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dbv Technologies SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Dbv Technologies SA Highlights
StrengthsRisks
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.64M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.64M.
Overvalued
The company’s latest PE is -3.52, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 17.36M shares, increasing 26.66% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 432.97K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
38.333
Target Price
+139.58%
Upside Space
Dbv Technologies SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Dbv Technologies SA Info
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Ticker SymbolDBVT
CompanyDbv Technologies SA
CEOTasse (Daniel)
Websitehttps://www.dbv-technologies.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53031.200
+188.700 (+0.36%)
29552.700
+241.300 (+0.82%)
7505.600
+34.100 (+0.46%)
15059.000
+256.000 (+1.73%)
69451.000
+1303.000 (+1.91%)
6381.000
+28.200 (+0.44%)
68.953
+0.609 (+0.89%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.000
+55.090 (+1.34%)
FAQs
What is the current price of Dbv Technologies SA (DBVT)?
The current price of Dbv Technologies SA (DBVT) is 15.82.
What is the symbol of Dbv Technologies SA?
The ticker symbol of Dbv Technologies SA is DBVT.
What is the 52-week high of Dbv Technologies SA?
The 52-week high of Dbv Technologies SA is 26.18.
What is the 52-week low of Dbv Technologies SA?
The 52-week low of Dbv Technologies SA is 7.53.
What is the market capitalization of Dbv Technologies SA?
The market capitalization of Dbv Technologies SA is 745.43M.
Is Dbv Technologies SA (DBVT) currently rated as Buy, Hold, or Sell?
According to analysts, Dbv Technologies SA (DBVT) has an overall rating of Buy, with a price target of 38.33.
What is the Earnings Per Share (EPS TTM) of Dbv Technologies SA (DBVT)?
The Earnings Per Share (EPS TTM) of Dbv Technologies SA (DBVT) is -5.26.